Biosimilar Equal to Natalizumab for Relapsing-Remitting MS Biosimilar Equal to Natalizumab for Relapsing-Remitting MS
A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 27, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS
(MedPage Today) -- Autologous hematopoietic stem cell transplantation (AHSCT) was not superior in preventing relapses or reducing disability progression than natalizumab (Tysabri) in progressive multiple sclerosis (MS), new research suggested... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 31, 2022 Category: Neurology Source Type: news

' Reassuring Data' for Two Multiple Sclerosis Meds in Pregnancy'Reassuring Data' for Two Multiple Sclerosis Meds in Pregnancy
Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 28, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Patient-Reported Outcomes Similar With Extended Natalizumab Dosing Interval
(MedPage Today) -- No significant differences emerged in patient-reported outcomes among relapsing-remitting multiple sclerosis (MS) patients who received natalizumab (Tysabri) every 6 weeks (Q6W) versus every 4 weeks (Q4W), an analysis of data... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - June 9, 2022 Category: Neurology Source Type: news

Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy
Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 5, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Stopping MS Med in Pregnancy Tied to High Disability Risk Stopping MS Med in Pregnancy Tied to High Disability Risk
Women with MS who stop taking natalizumab during pregnancy are at a significantly increased risk of relapse-related disability up to 1 year after delivery, new research shows.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 7, 2022 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

Rituximab Trumps Natalizumab in MS Relapse Rituximab Trumps Natalizumab in MS Relapse
Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 3, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab Better Than Natalizumab for MS Relapses? Rituximab Better Than Natalizumab for MS Relapses?
Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 3, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab More Effective Than Other MS Treatments? Rituximab More Effective Than Other MS Treatments?
Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 15, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab Postinfusion Reactions Rare; Is Monitoring Necessary? Natalizumab Postinfusion Reactions Rare; Is Monitoring Necessary?
Several studies show these infusion reactions are very rare and mild; the required monitoring presents particular risk during the COVID pandemic.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 4, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Kessler Foundation studies effects of Tysabri on cognitive fatigue in multiple sclerosis
(Kessler Foundation) The majority of persons with MS have cognitive fatigue, which can adversely affect their ability to perform everyday life activities. Although 40% consider cognitive fatigue their most troubling symptom, there are few treatment options. None of the pharmacological interventions used to slow progression of physical disability are indicated for treating cognitive fatigue. This is the first study to explore whether treatment with Tysabri may alleviate cognitive fatigue in individuals with MS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 19, 2021 Category: International Medicine & Public Health Source Type: news

Natalizumab Switch to Moderate-Efficacy DMT Ups Disability Risk Natalizumab Switch to Moderate-Efficacy DMT Ups Disability Risk
Patients who switched to another high-efficacy therapy had improved disability and inflammatory outcomes.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 27, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Natalizumab Bests Fingolimod for Relapsing-Remitting MS Natalizumab Bests Fingolimod for Relapsing-Remitting MS
In a head-to-head comparison, natalizumab was superior to fingolimod for evidence of disease activity at 1 year for patients with active relapsing-remitting multiple sclerosis.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 13, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Different Infection Risks for MS Treatments Different Infection Risks for MS Treatments
New study results suggest rituximab has a higher risk of serious infections than fingolimod or natalizumab, but a lower risk of herpetic infections.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 10, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New Data on Natalizumab During Pregnancy in MS New Data on Natalizumab During Pregnancy in MS
Women with multiple sclerosis who continued to receive the drug during pregnancy had a much lower risk of relapses, according to a new Italian observational study.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news